User: Guest  Login
Title:

Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial.

Document type:
Clinical Trial, Phase II; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
Author(s):
Kunzmann, Volker; Siveke, Jens T; Algül, Hana; Goekkurt, Eray; Siegler, Gabriele; Martens, Uwe; Waldschmidt, Dirk; Pelzer, Uwe; Fuchs, Martin; Kullmann, Frank; Boeck, Stefan; Ettrich, Thomas J; Held, Swantje; Keller, Ralph; Klein, Ingo; Germer, Christoph-Thomas; Stein, Hubert; Friess, Helmut; Bahra, Marcus; Jakobs, Ralf; Hartlapp, Ingo; Heinemann, Volker
Abstract:
BACKGROUND: The optimal preoperative treatment for locally advanced pancreatic cancer is unknown. We aimed to compare the efficacy and safety of nab-paclitaxel plus gemcitabine with nab-paclitaxel plus gemcitabine followed by fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) as multidrug induction chemotherapy regimens in locally advanced pancreatic cancer. METHODS: In this open-label, multicentre, randomised phase 2 study, done at 28 centres in Germany, eligible patients were a...     »
Journal title abbreviation:
Lancet Gastroenterol Hepatol
Year:
2021
Journal volume:
6
Journal issue:
2
Pages contribution:
128-138
Fulltext / DOI:
doi:10.1016/S2468-1253(20)30330-7
Pubmed ID:
http://view.ncbi.nlm.nih.gov/pubmed/33338442
TUM Institution:
608; 679; Klinik und Poliklinik für Chirurgie; Lehrstuhl für Tumormetabolismus (Prof. Algül)
 BibTeX